-
Raymond James Reviews Gilead Pipelines, Takes Bullish Stance On Pharma Stock
Thursday, June 28, 2018 - 1:42pm | 455Read More...The biotechnology sector remains highly competitive, and investors willing to take on a stock with a high-risk, high-growth profile may want to consider Gilead Sciences, Inc. (NASDAQ: GILD), according to Raymond James. The Analyst Raymond James' Steven Seedhouse initiated coverage of...
-
Credit Suisse: Street Expectations 'Too High' For Gilead's Hep C Therapy
Wednesday, December 20, 2017 - 12:23pm | 367Read More...The Street may be too optimistic in its outlook for Gilead Sciences, Inc. (NASDAQ: GILD) — and this isn't a bullish indicator, according to Credit Suisse. The Analyst Credit Suisse's Alethia Young downgraded Gilead's stock rating from Outperform to Neutral with a price target...
-
Gilead's Q1 Fails To Impress, But Strength Of Pipeline Not Reflected In Current Share Price
Wednesday, May 3, 2017 - 10:46am | 355Read More...BMO Capital Markets' M. Ian Somaiya maintained a Market Perform rating on Gilead Sciences, Inc. (NASDAQ: GILD) with a price target boosted from $75 to $76 after the company reported its first quarter results. Gilead's reported revenues of $6.5 billion fell short of the $6.66 billion...
-
Jefferies Sees Limited Impact To Gilead From Regulus' HCV Candidate's Clinical Hold
Tuesday, June 28, 2016 - 3:27pm | 214Read More...Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) were down almost 48 percent on Tuesday, after the company said Monday the FDA had placed its lead product candidate, RG-101 – for the treatment of hepatitis C virus infection, on clinical hold. Following the news, Jefferies analysts...
-
Here's Why Regulus Therapeutics Gained 20%
Wednesday, February 17, 2016 - 12:09pm | 252Read More...Shares of Regulus Therapeutics Inc (NASDAQ: RGLS) were trading higher by nearly 20 percent late Wednesday morning after the company announced interim results from an ongoing Phase 2 study. Regulus Therapeutics' Phase 2 study of RG-101 for the treatment of Hepatitis C Virus infection (HCV) was...
-
Merck Confirms FDA Approval Of Hep C Drug At A Cost Of $54,600 Per Patient
Friday, January 29, 2016 - 11:29am | 364Read More...Merck & Co., Inc. (NYSE: MRK) confirmed after Thursday's market close that the U.S. Food and Drug Administration has approved ZEPATIER for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype (GT) 1 or GT4 infection. Shares of Merck were trading higher by 1.32...
-
Gilead Stock Whiffs, But One Pro Remains Bullish
Wednesday, October 28, 2015 - 1:26pm | 432Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading lower by more than 3 percent Wednesday afternoon. The company reported an upbeat third-quarter print, while full year guidance may have disappointed some investors. Wendy Lam of Oppenheimer maintained an Outperform rating and $...
-
Wall Street Defends AbbVie, Says Reaction Is Overdone
Friday, October 23, 2015 - 8:07am | 507Read More...Shares of AbbVie Inc (NYSE: ABBV) plunged more than 10 percent on Thursday, hitting a new 52-week low of $45.45. The FDA requested that the company update its HCV treatment Viekira's label to reflect several cases of liver injury. Matthew Harrison of Morgan Stanley and Chris Schott of...
-
Oppenheimer Incrementally More Bullish on Gilead, Remains Cautious On Vertex
Tuesday, October 20, 2015 - 11:00am | 622Read More...Wendy Lam of Oppenheimer maintained an Outperform rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) and Perform rating on shares of Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Lam noted that Gilead's two core franchises offer a "durable foundation" of substantial...
-
Gilead Sciences: Here's What A Bull And A Bear Are Saying
Wednesday, July 29, 2015 - 9:34am | 483Read More...Shares of Gilead Sciences, Inc. (NASDAQ: GILD) were trading higher by more than 4 percent Wednesday after the company reported better-than-expected earnings for its second quarter. Here are opposing views of what two of Wall Street's top analysts are saying. Bank Of America: Long-Term...
-
Nomura's Takeaways From Meeting With Gilead Sciences' Management
Friday, January 16, 2015 - 10:17am | 175Read More...Ian Somaiya of Nomura on Friday reiterated a Buy rating on shares of Gilead Sciences, Inc. (NASDAQ: GILD) with a $146 price target following a meeting with the company's management team. Somaiya notes that additional insight was gained into: 1) HCV pricing and payor negations, 2) potential...
